Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. Read more about Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Read more about Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy. Read more about Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy.
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy. Read more about Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance). Read more about Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. Read more about Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. Read more about Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance. Read more about Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Read more about Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma. Read more about Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
